22

Polymetal: Business update

Retrieved on: 
Thursday, June 23, 2022
Sanction, Contract, Gold, Public expenditure, MHA, US, Union, Central Bank of Russia, Environment, Executive Order 13936, Central bank, Central, Company, 22, Raosaheb Rangnath Borade, Kaspersky bans and allegations of Russian government ties, Office of Foreign Assets Control, Pressure, USD, Turnaround ADR, Solution, Program, Mining, Legislation, RUB, National Settlement Depository (Russia), Board, Executive, Climate Disclosure Standards Board, COVID, Cryptocurrency, Security (finance), Bank, Rail transport, Prognoz, Polymetal, Euroclear, NSD, Group

Polymetal provides an update on its business, including the current impact of sanctions against Russia.

Key Points: 
  • Polymetal provides an update on its business, including the current impact of sanctions against Russia.
  • Since the previous update, Japan joined western countries and imposed additional sanctions against Russia prohibiting exports of industrial goods and technologies.
  • The Board and the management continuously evaluate stability, liquidity and solvency of the business in light of multiple external uncertainties.
  • The Board and the management strongly believe that share buy-backs are presently inappropriate given short-term liquidity challenges, grave business uncertainties, and NSD challenges outlined above.

Elucida Oncology to Present Trials in Progress Poster for Phase 1/2 Study of ELU001 in Patients with Advanced, Recurrent, or Refractory Cancers Overexpressing FRα at 2022 American Society of Clinical Oncology Annual Meeting

Retrieved on: 
Wednesday, June 1, 2022
12, Colorectal cancer, Large-cell lung carcinoma, Company, Endometrial cancer, Society, Control, 22, American Society of Clinical Oncology, Toxicity, Trial, ASCO, Drug, Half-life, CDC, Neoplasm, Part, MTD, Ovarian cancer, Stomach, GLOBE, Patient, Target, Folate, Cholangiocarcinoma, Index (publishing), Silicon, Safety, Pharmaceutical industry, Vaccine

The Trials in Progress poster presentation will summarize the proposed mechanism of ELU001, preclinical observations to date, and the clinical trial design.

Key Points: 
  • The Trials in Progress poster presentation will summarize the proposed mechanism of ELU001, preclinical observations to date, and the clinical trial design.
  • ELU001 is a novel, first-in-class, new molecular entity described as a CDot Drug Conjugate (CDC).
  • ELU001s high avidity is believed to promote internalization into FR overexpressing cancer cells, selectively delivering its payload.
  • CDCs are designed to penetrate deeper into tumors and deliver a significantly higher payload compared to antibody drug conjugates (ADCs).